Drug and Therapy Development for Triple Negative Breast Cancer

HISTORY OF BREAST CANCER Early-Stage Diagnosis of Breast Cancer: Amelioration in Approaches DNA replication stress and genome instability in breast cancer Recent advancement of nanotherapeutics to treat breast cancer HER Receptor in Breast Cancer Human endogenous retroviruses in triple negative breast cancer NOVEL DRUG DISCOVERY AND DEVELOPMENT Development in Drug repurposing for the treatment of acute leukemia complicating metastatic breast cancer Novel pharmaceutical nanomaterials to advance the current breast cancer treatment - Current trends and future perspective ADVANCED TECHNOLOGIES IN BREAST CANCER THERAPY Artificial intelligence-driven decisions in breast cancer diagnosis Establishing nanotechnology-based drug development for triple-negative breast cancer treatment Etiology and therapy of hormone receptor positive breast cancer Donor-acceptor based heterocyclic compounds as chemotherapy and photothermal agents in treatment of breast cancer cell REGULATORY, CLINICAL ASPECTS AND CASE STUDIES An insight into drug regulatory affairs and the procedures A comprehensive review of some heat shock proteins in the development and progression of human breast cancer Nanoparticle-based therapeutics for triple negative breast cancer

Dr. Pravin Kendrekar, School of Natural Sciences, University of Central Lancashire, Preston, UK. Dr. Vinayak Adimule, Angadi Institute of Technology and Management, Belagavi, India. Dr. Tara Hurst, Pandemic Sciences Institute, University of Oxford, Oxford, UK.